Document:

exv4w1

Exhibit 4.1

WARRANT AGREEMENT

     THIS WARRANT AGREEMENT (this “Agreement”), dated as of December 15, 2010, is entered into by
and between Aastrom Biosciences, Inc., a Michigan corporation (the “Company”), and Continental
Stock Transfer & Trust Company, a New York corporation (the “Warrant Agent”).

     WHEREAS, the Company is engaged in a public offering (the “Public Offering”) of units (the
“Units”) and, in connection therewith, has determined to issue and deliver up to 10,000,000
Warrants (the “Warrants”), subject to adjustment as provided herein, to the public investors, each
of such Warrants evidencing the right of the holder thereof to purchase one share of the Company’s
common stock, no par value (the “Common Stock”);

     WHEREAS, the Company has filed with the Securities and Exchange Commission a Registration
Statement on Form S-3, No. 333-170581 (the “Registration Statement”), for the registration, under
the Securities Act of 1933, as amended (the “Act”), of, among other securities, the Warrants and
the Common Stock issuable upon exercise of the Warrants (the “Warrant Shares”);

     WHEREAS, the Company desires the Warrant Agent to act on behalf of the Company, and the
Warrant Agent is willing to so act, in connection with the issuance, registration, transfer,
exchange, redemption and exercise of the Warrants;

     WHEREAS, the Company desires to provide for the form and provisions of the Warrants, the terms
upon which they shall be issued and exercised, and the respective rights, limitation of rights, and
immunities of the Company, the Warrant Agent, and the holders of the Warrants; and

     WHEREAS, all acts and things have been done and performed that are necessary to make the
Warrants, when executed on behalf of the Company and countersigned by or on behalf of the Warrant
Agent, as provided herein, the valid, binding and legal obligations of the Company, and to
authorize the execution and delivery of this Agreement.

     NOW, THEREFORE, in consideration of the mutual agreements herein contained, the parties hereto
agree as follows:

1. Appointment of Warrant Agent. The Company hereby appoints the Warrant Agent to act as
agent for the Company for the Warrants, and the Warrant Agent hereby accepts such appointment and
agrees to perform the same in accordance with the terms and conditions set forth in this Agreement.

2. Warrants.

     2.1 Form of Warrant. Each Warrant shall be (a) issued in registered form only, (b) in
substantially the forms of Exhibit A, hereto, the provisions of which are incorporated
herein, and (c) signed by, or bear the facsimile signature of, the President and the Secretary of
the Company. In the event the person whose facsimile signature has been placed upon any Warrant
shall have

 

 

ceased to serve in the capacity in which such person signed the Warrant before such Warrant is
issued, it may be issued with the same effect as if he or she had not ceased to be such at the date
of issuance.

     2.2 Effect of Countersignature. Unless and until countersigned by the Warrant Agent
pursuant to this Agreement, a Warrant shall be invalid and of no effect and may not be exercised by
the holder thereof.

     2.3 Registration.

          2.3.1 Warrant Register. The Warrant Agent shall maintain books (the “Warrant
Register”) for the registration of the original issuance and transfers of the Warrants. Upon the
initial issuance of the Warrants, the Warrant Agent shall issue and register the Warrants in the
names of the respective holders thereof in such denominations and otherwise in accordance with
instructions delivered to the Warrant Agent by the Company.

          2.3.2 Registered Holder. Prior to due presentment for registration of transfer of any
Warrant, the Company and the Warrant Agent may deem and treat the person in whose name such Warrant
shall be registered upon the Warrant Register (the “registered holder”), as the absolute owner of
such Warrant and of each Warrant represented thereby (notwithstanding any notation of ownership or
other writing on the warrant certificate made by anyone other than the Company or the Warrant
Agent), for the purpose of any exercise thereof, and for all other purposes, and neither the
Company nor the Warrant Agent shall be affected by any notice to the contrary.

3. Terms and Exercise of Warrants.

     3.1 Exercise Price. Each Warrant shall, when countersigned by the Warrant Agent,
entitle the registered holder thereof, subject to the provisions of such Warrant and of this
Warrant Agreement, to purchase from the Company the number of shares of Common Stock stated
therein, at the price of $3.22 per whole share (the “Exercise Price”), subject to the adjustments
provided in Section 4 hereof .

     3.2 Duration of Warrants. A Warrant may be exercised only during the period (“Exercise
Period”) commencing on the date of issuance and terminating at 5:30 p.m., New York City time five
years from the start of the Exercise Period (the “Expiration Date”). Each Warrant not exercised on
or before the Expiration Date shall become void, and all rights thereunder and all rights in
respect thereof under this Agreement shall cease at the close of business on the Expiration Date.

     3.3 Exercise of Warrants.

               (a) Methods of Exercise. A registered holder may exercise the Warrants through a cash
exercise (a “Cash Exercise”) or through a cashless exercise (a “Cashless Exercise”) pursuant to
Section 3.3(b) below. This Warrant may be exercised by the registered holder, in whole or in
part, by delivery (whether via facsimile or otherwise) to the Company of

 

 

the Form of Election to Purchase, in the form attached as Exhibit A to the Warrant (the
“Exercise Notice”), indicating the registered holder’s election to exercise this Warrant. Within
one (1) Trading Day following an exercise of the Warrant as aforesaid, the registered holder shall
deliver payment to the Company of an amount equal to the Exercise Price in effect on the date of
such exercise multiplied by the number of Warrant Shares as to which this Warrant was so exercised
(the “Aggregate Exercise Price”) in a manner set forth in subsection (c) below if the registered holder
did not notify the Company in such Exercise Notice that such exercise was made pursuant to a
Cashless Exercise. The registered holder shall not be required to deliver the original of this
Warrant in order to effect an exercise hereunder. Execution and delivery of an Exercise Notice with
respect to less than all of the Warrant Shares shall have the same effect as cancellation of the
original of the Warrant and issuance of a new Warrant evidencing the right to purchase the
remaining number of Warrant Shares. Execution and delivery of an Exercise Notice for all of the
then-remaining Warrant Shares shall have the same effect as cancellation of the original of this
Warrant after delivery of the Warrant Shares in accordance with the terms hereof. On or before the
second (2nd) Trading Day following the date on which the Company has received an Exercise Notice,
the Company shall transmit by facsimile or electronic mail an acknowledgment of confirmation of
receipt of such Exercise Notice, in the form attached to the Warrant as Exhibit B, to the
registered holder and the Company’s transfer agent (the “Transfer Agent”). On or before the third
(3rd) Trading Day following the date on which the Company has received such Exercise Notice, the
Company shall (X) provided that the Transfer Agent is participating in The Depository Trust Company
(“DTC”) Fast Automated Securities Transfer Program, upon the request of the registered holder,
credit such aggregate number of shares of Common Stock to which the registered holder is entitled
pursuant to such exercise to the registered holder’s or its designee’s balance account with DTC
through its Deposit/ Withdrawal at Custodian system, or (Y) if the Transfer Agent is not
participating in the DTC Fast Automated Securities Transfer Program, issue and deliver to the
registered holder or, at the registered holder’s instruction pursuant to the Exercise Notice, the
registered holder’s agent or designee, in each case, sent by reputable overnight courier to the
address as specified in the applicable Exercise Notice, a certificate, registered in the Company’s
share register in the name of the registered holder or its designee (as indicated in the applicable Exercise
Notice), for the number of shares of Common Stock to which the registered holder is entitled
pursuant to such exercise. Upon delivery of an Exercise Notice, the registered holder shall be
deemed for all corporate purposes to have become the holder of record of the Warrant Shares with
respect to which this Warrant has been exercised, irrespective of the date such Warrant Shares are
credited to the registered holder’s DTC account or the date of delivery of the certificates
evidencing such Warrant Shares (as the case may be). The Company shall pay any and all taxes and
fees which may be payable with respect to the issuance and delivery of Warrant Shares upon exercise
of this Warrant.

               (b) Cashless Exercise. The registered holder may effect a Cashless Exercise by noting on the
Form of Election to Purchase that the registered holder wishes to effect a Cashless Exercise, upon
which the Company shall issue, or cause to be issued, to the registered holder the number of
Warrant Shares determined as follows:

X = Y x [(A-B)/C]

     where:

 

 

X = the number of Warrant

Shares to be issued to the

registered holder;

Y = the number of Warrant

Shares with respect to which the

Warrant Certificates are being

exercised;

A = the average of the

Closing Sale Prices of the shares

of Common stock (as reported by

Bloomberg Financial Markets) for

the five (5) consecutive trading

days ending on the date

immediately preceding the Date of

Exercise;

B = the Exercise Price; and

C= the Closing Sale Price of the

shares of Common stock (as reported by

Bloomberg Financial Markets) on the

Date of Exercise.

     “Closing Sale Price” means, for any security as of any date, the last trade price for such
security on the principal securities exchange or trading market for such security, as reported by
Bloomberg Financial Markets, or, if such exchange or trading market begins to operate on an
extended hours basis and does not designate the last trade price, then the last trade price of such
security prior to 4:00 P.M., New York City time, as reported by Bloomberg Financial Markets, or if
the foregoing do not apply, the last trade price of such security in the over-the-counter market on
the electronic bulletin board for such security as reported by Bloomberg Financial Markets, or, if
no last trade price is reported for such security by Bloomberg Financial Markets, the average of
the bid prices, or the ask prices, respectively, of any market makers for such security as reported
in the “pink sheets” by Pink Sheets LLC. If the Closing Sale Price cannot be calculated for a
security on a particular date on any of the foregoing bases, the Closing Sale Price of such
security on such date shall be the fair market value as mutually determined by the Company and the
registered holder. If the Company and the registered holder are unable to agree upon the fair
market value of such security, then the Board of Directors of the Company shall use its good faith
judgment to determine the fair market value. The Board of Directors’ determination shall be binding
upon all parties absent demonstrable error. All such determinations shall be appropriately adjusted
for any stock dividend, stock split, stock combination or other similar transaction during the
applicable calculation period.

               (c) If a registered holder elects to exercise the Warrants through a Cash Exercise, then
subject to the provisions of the Warrant and this Warrant Agreement, a Warrant, when countersigned
by the Warrant Agent, may be exercised by the registered holder thereof by surrendering the
Exercise Notice at the office of the Warrant Agent, or at the office of its successor as Warrant
Agent, in the Borough of Manhattan, City and State of New York, as set forth in the Warrant, duly
executed, provided that the registered holder shall pay the Aggregate Exercise Price in full, in
lawful money of the United States, in good certified check or good bank draft payable to the order
of the Company or via wire transfer of immediately available funds payable to the order of the
Company (or as otherwise agreed to by the Company).

               (d) Company’s Failure to Timely Deliver Securities. If the Company shall fail for any reason
or for no reason to issue or cause the Warrant Agent to issue to the registered
holder within three (3) Business Days of exercise in compliance with the terms of this Section
3,

 

 

a certificate for the number of shares of Common Stock to which the registered holder is
entitled and register such shares of Common Stock on the Company’s share register or to credit the
registered holder’s balance account with DTC for such number of shares of Common Stock to which the
registered holder is entitled upon the registered holder’s exercise of its Warrant Certificate, and
if on or after such Trading Day the registered holder purchases (in an open market transaction or
otherwise) shares of Common Stock to deliver in satisfaction of a sale by the registered holder of
shares of Common Stock issuable upon such exercise that the registered holder anticipated receiving
from the Company (a “Buy-In”), then the Company shall, within three (3) Business Days after the
registered holder’s request and in the registered holder’s discretion, either (i) pay cash to the
registered holder in an amount equal to the registered holder’s total purchase price (including
brokerage commissions, if any) for the shares of Common Stock so purchased (the “Buy-In Price”), at
which point the Company’s obligation to deliver such certificate (and to issue such Warrant Shares
or credit such registered holder’s balance account at DTC) shall terminate, or (ii) promptly honor
its obligation to deliver to the registered holder a certificate or certificates representing such
Warrant Shares or credit such registered holder’s balance account at DTC and pay cash to the
registered holder in an amount equal to the excess (if any) of the Buy-In Price over the product of
(A) such number of shares of Common Stock, times (B) the Weighted Average Price on the date of
exercise. “Weighted Average Price” means, for any security as of any date, the dollar
volume-weighted average price for such security on the Principal Market during the period beginning
at 9:30:01 a.m., New York City time, and ending at 4:00:00 p.m., New York City time, as reported by
Bloomberg through its “Volume at Price” function or, if the foregoing does not apply, the dollar
volume-weighted average price of such security in the over-the-counter market on the electronic
bulletin board for such security during the period beginning at 9:30:01 a.m., New York City time,
and ending at 4:00:00 p.m., New York City time, as reported by Bloomberg, or, if no dollar
volume-weighted average price is reported for such security by Bloomberg for such hours, the
average of the highest closing bid price and the lowest closing ask price of any of the market
makers for such security as reported in the “pink sheets” by Pink Sheets LLC (formerly the National
Quotation Bureau, Inc.). If the Weighted Average Price cannot be calculated for such security on
such date on any of the foregoing bases, the Weighted Average Price of such security on such date
shall be the fair market value as mutually determined by the Company and the registered holder. If the Company
and the registered holder are unable to agree upon the fair market value of such security, then such dispute
shall be resolved pursuant to Section 9.10 with the term “Weighted Average Price” being substituted
for the term “Exercise Price.” All such determinations shall be appropriately adjusted for any
share dividend, share split or other similar transaction during such period.

               (e) Disputes. In the case of a dispute as to the determination of the Exercise Price or the
arithmetic calculation of the number of Warrant Shares to be issued pursuant to the terms hereof,
the Company shall promptly issue to the registered holder the number of Warrant Shares that are not
disputed and resolve such dispute in accordance with Section 9.10.

     3.4 Valid Issuance. All shares of Common Stock issued upon the proper exercise of a
Warrant in conformity with this Agreement shall be validly issued, fully paid and nonassessable.

     3.5 Date of Issuance. Each person in whose name any such certificate for shares of
Common Stock is issued shall for all purposes be deemed to have become the holder of record of

 

 

such shares on the date on which the Exercise Notice is delivered to the Company, irrespective of the
date of delivery of such certificate, except that, if the date of such surrender and payment is a
date when the stock transfer books of the Company are closed, such person shall be deemed to have
become the holder of such shares at the close of business on the next succeeding date on which the
stock transfer books are open.

4. Adjustments.

     4.1 Stock Dividends and Splits.

               (a) If the Company, (i) pays a stock dividend on its Common Stock or otherwise makes a
distribution on any class of capital stock that is payable in shares of Common Stock, (ii)
subdivides its outstanding shares of Common Stock into a larger number of shares, (iii) combines
its outstanding shares of Common Stock into a smaller number of shares or (iv) issues by
reclassification of shares of Common Stock any shares of capital stock of the Company, then in each
such case the Exercise Price shall be multiplied by a fraction, the numerator of which shall be the
number of shares of Common Stock outstanding immediately before such event and the denominator of
which shall be the number of shares of Common Stock outstanding immediately after such event and
the number of Warrant Shares that may be purchased upon exercise of this Warrant shall be increased
or decreased proportionately. Any adjustment made pursuant to clause (i) of this paragraph shall
become effective immediately after the record date for the determination of stockholders entitled
to receive such dividend or distribution, and any adjustment pursuant to clause (ii), (iii) or (iv)
of this paragraph shall become effective immediately after the effective date of such subdivision
or combination or reclassification.

               (b) In addition to any adjustments pursuant to Section 4.1(a) above, if at any time the
Company grants, issues or sells any warrants or other rights to subscribe for or to purchase, or
any options for the purchase of, Common Stock or any stock or security convertible into or
exchangeable for Common Stock (such warrants, rights or options being called “Options”, and such
convertible or exchangeable stock or securities being called “Convertible Securities”) or rights to
purchase stock, warrants, securities or other property pro rata to the record holders of any class
of shares of Common Stock (the “Purchase Rights”), then the registered holder will be entitled to
acquire, upon the same terms as such Purchase Rights were acquired by such record holders of such
class of Common Stock, the aggregate Purchase Rights which the registered holder could have
acquired if the registered holder had held the number of shares of Common Stock acquirable upon
complete exercise of the Warrant (without regard to any limitations on exercise hereof, including
without limitation, the Maximum Percentage) immediately before the date on which a record is taken
for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date
as of which the record holders of shares of Common Stock are to be determined for the grant, issue
or sale of such Purchase Rights (provided, however, to the extent that the registered holder’s
right to participate in any such Purchase Right would result in the registered holder exceeding the
Maximum Percentage, then the registered holder shall not be entitled to participate in such
Purchase Right to such extent (or beneficial ownership of such
shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase

 

 

Right to such extent shall be held in abeyance for the registered holder until such time, if ever,
as its right thereto would not result in the registered holder exceeding the Maximum Percentage).

     4.2 Pro Rata Distributions. If the Company, at any time while the Warrants are
outstanding, distributes to all holders of Common Stock for no consideration (i) evidences of its
indebtedness, (ii) any security (other than a distribution of Common Stock covered by the preceding
Section) or (iii) rights, options or warrants to subscribe for or purchase any security, or (iv)
any other asset (including cash or cash dividends) (in each case, a “Distribution”), then, in each
such case, the registered holder shall be entitled to participate in such Distribution to the same
extent that the registered holder would have participated therein if the registered holder had held
the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without
regard to any limitations on exercise hereof, including without limitation, the Maximum Percentage
(as defined below)) immediately before the date on which a record is taken for such Distribution,
or, if no such record is taken, the date as of which the record holders of shares of Common Stock
are to be determined for the participation in such Distribution (provided, however, to the extent
that the registered holder’s right to participate in any such Distributions would result in the
registered holder exceeding the Maximum Percentage, then the registered holder shall not be
entitled to participate in such Distribution to such extent (or the beneficial ownership of any
such shares of Common Stock as a result of such Distribution to such extent) and such Distribution
to such extent shall be held in abeyance for the benefit of the registered holder until such time,
if ever, as its right thereto would not result in the registered holder exceeding the Maximum
Percentage).

     4.3 Fundamental Transactions. If (i) the Company effects any merger or consolidation
of the Company with or into another Person, in which the Company is not the survivor or the
stockholders of the Company immediately prior to such merger or consolidation do not own, directly
or indirectly, at least 50.1% of the voting securities of the surviving entity, (ii) the Company
effects any sale, lease, assignment, transfer, conveyance or other distribution of all or
substantially all of its assets to a third party, in each case, in one or a series of related
transactions, (iii) any direct or indirect purchase offer, tender offer or exchange offer (whether
by the Company or another Person) is completed pursuant to which at least holders of a majority of
the outstanding shares of Common Stock are permitted to tender or exchange their shares for other
securities, cash or property, (iv) the Company, directly or indirectly, in one or more related
transactions, effects any reorganization, recapitalization or reclassification of the Common Stock
or any compulsory share exchange pursuant to which the Common Stock is effectively converted into
or exchanged for other securities, cash or property (other than as a result of a subdivision or
combination of shares of Common Stock covered by Section 4.1 above), or (v) the Company, directly
or indirectly, in one or more related transactions consummates a stock or share purchase agreement
or other business combination (including, without limitation, a reorganization, recapitalization,
spin-off or scheme of arrangement) with another person whereby such other person acquires more than
50% of the outstanding shares of Common Stock (not including any shares of Common Stock held by the
other person or other persons making or party to, or associated or affiliated with the other
persons making or party to, such stock or share purchase agreement or other business combination)
(in any such case, a “Fundamental Transaction”), then the registered holder shall have the right
thereafter to receive, upon exercise of the Warrant, the
same amount and kind of securities, cash or property as it would have been entitled to receive

 

 

upon the occurrence of such Fundamental Transaction if it had been, immediately prior to such
Fundamental Transaction, the holder of the number of Warrant Shares then issuable upon exercise in
full of the Warrant without regard to any limitations on exercise contained in the Warrant (the
“Alternate Consideration”). The Company shall not effect any such Fundamental Transaction unless
prior to or simultaneously with the consummation thereof, any successor to the Company, surviving
entity or the corporation purchasing or otherwise acquiring such assets or other appropriate
corporation or Person shall assume the Warrant and the obligation to deliver to the registered
holder, such Alternate Consideration as, in accordance with the foregoing provisions, the
registered holder may be entitled to receive, and the other obligations under the Warrant.
Notwithstanding the foregoing at the request of the registered holder delivered at any time
commencing on the earlier to occur of the public disclosure of any Fundamental Transaction or the
consummation of any Fundamental Transaction through the date that is ninety (90) days after the
later to occur of (i) the public disclosure of such Fundamental Transaction , (ii) the consummation
of such Fundamental Transaction and (iii) the registered holder becoming aware of such Fundamental
Transaction if such Fundamental Transaction was not publicly disclosed, the Company or the
Successor Entity (as the case may be) shall purchase the Warrant from the registered holder on the
date of such request by paying to the registered holder cash in an amount equal to the Black
Scholes Value (as defined below). For purposes hereof, “Black Scholes Value” means the value of
the unexercised portion of the Warrant remaining on the date of the registered holder’s request
pursuant, which value is calculated using the Black Scholes Option Pricing Model obtained from the
“OV” function on Bloomberg utilizing (i) an underlying price per share equal to the greater of (1)
the highest Closing Sale Price of the Common Stock during the period beginning on the Trading Day
immediately preceding the earlier to occur of the public disclosure or consummation of the
applicable Fundamental Transaction and ending on the Trading Day of the registered holder’s request
pursuant to this Section and (2) the sum of the price per share being offered in cash in the
applicable Fundamental Transaction (if any) plus the value of the non-cash consideration being
offered in the applicable Fundamental Transaction (if any), (ii) a strike price equal to the
Exercise Price in effect on the of date of the registered holder’s request pursuant to this Section, (iii) a
risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the greater
of (1) the remaining term of the Warrant as of the date of the registered holder’s request pursuant to this
Section and (2) the remaining term of this Warrant as of the date of consummation of the applicable
Fundamental Transaction or as of the date of the registered holder’s request pursuant to this
Section if such request is prior to the date of the consummation of the applicable Fundamental
Transaction and (iv) an expected volatility equal to the greater of 100% and the 30 day volatility
obtained from the HVT function on Bloomberg (determined utilizing a 365 day annualization factor)
as of the Trading Day immediately following the earlier to occur of the public disclosure or
consummation of the applicable Fundamental Transaction.

     4.4 Subsequent Equity Sales. (i) Except as provided in Section 4.4(iii) below, if and
whenever the Company shall issue or sell, or is, in accordance with Section 4.4(ii)(l) through
4.4(ii)(5) below, deemed to have issued or sold, any shares of Common Stock or Common Stock
Equivalents entitling any Person to acquire shares of Common Stock for no consideration or for a
consideration per share (the “New Issuance Price”) less than the Exercise Price in effect
immediately prior to the time of such issue or sale (the “Applicable Price”), then and in each
such case (a “Trigger Issuance”) the then-existing Exercise Price shall be reduced as of the
close of business on the effective date of the Trigger Issuance to the New Issuance Price.

 

 

     As used in this Warrant, the term “Common Stock Equivalents” means any securities of the
Company or any Subsidiary which would entitle the holder thereof to acquire at any time Common
Stock, including, without limitation, any debt, preferred stock, rights, options, warrants or other
instrument that is at any time convertible into or exchangeable for, or otherwise entitles the
holder thereof to receive, Common Stock or other securities that entitle the holder to receive,
directly or indirectly, Common Stock.

          (ii) For purposes of this Section 4.4, the following Sections 4.4(ii)(l) to 4.4(ii)(5) shall
also be applicable:

               (1) Issuance of Options. If the Company in any manner grants or sells any Options and the
lowest price per share for which one share of Common Stock is issuable upon the exercise of any
such Option or upon conversion, exercise or exchange of any Convertible Securities issuable upon
exercise of any such Option is less than the Applicable Price, then such share of Common Stock
shall be deemed to be outstanding and to have been issued and sold by the Company at the time of
the granting or sale of such Option for such price per share. For purposes of this Section
4.4(ii)(1), the “lowest price per share for which one share of Common Stock is issuable upon the
exercise of any such Options or upon conversion, exercise or exchange of any Convertible Securities
issuable upon exercise of any such Option” shall be equal to (1) the lower of (x) the sum of the
lowest amounts of consideration (if any) received or receivable by the Company with respect to any
one share of Common Stock upon the granting or sale of such Option, upon exercise of such Option
and upon conversion, exercise or exchange of any Convertible Security issuable upon exercise of
such Option and (y) the lowest exercise price set forth in such Option for which one share of
Common Stock is issuable upon the exercise of any such Options or upon conversion, exercise or
exchange of any Convertible Securities issuable upon exercise of any such Option minus (2) the sum
of all amounts paid or payable to the holder of such Option (or any other Person) upon the granting
or sale of such Option, upon exercise of such Option and upon conversion, exercise or exchange of
any Convertible Security issuable upon exercise of such Option plus the value of any other
consideration received or receivable by, or benefit conferred on, the holder of such Option (or any
other Person). Except as contemplated below, no further adjustment of the Exercise Price shall be
made upon the actual issuance of such shares of Common Stock or of such Convertible Securities upon
the exercise of such Options or upon the actual issuance of such shares of Common Stock upon
conversion, exercise or exchange of such Convertible Securities.

               (2) Issuance of Convertible Securities. If the Company in any manner issues or sells any
Convertible Securities and the lowest price per share for which one share of Common Stock is
issuable upon the conversion, exercise or exchange thereof is less than the Applicable Price, then
such share of Common Stock shall be deemed to be outstanding and to have been issued and sold by
the Company at the time of the issuance or sale of such Convertible Securities for such price per
share. For the purposes of this Section 4.4(ii), the “lowest price per share for which one share
of Common Stock is issuable upon the conversion, exercise or exchange thereof” shall be equal to
(1) the lower of (x) the sum of the lowest amounts of
consideration (if any) received or receivable by the Company with respect to one share of
Common Stock upon the issuance or sale of the Convertible Security and upon conversion, exercise or
exchange of such Convertible Security and (y) the lowest conversion price set forth

 

 

in such Convertible Security for which one share of Common Stock is issuable upon conversion, exercise or
exchange thereof minus (2) the sum of all amounts paid or payable to the holder of such Convertible
Security (or any other Person) upon the issuance or sale of such Convertible Security plus the
value of any other consideration received or receivable by, or benefit conferred on, the holder of
such Convertible Security (or any other Person). Except as contemplated below, no further
adjustment of the Exercise Price shall be made upon the actual issuance of such shares of Common
Stock upon conversion, exercise or exchange of such Convertible Securities, and if any such issue
or sale of such Convertible Securities is made upon exercise of any Options for which adjustment of
this Warrant has been or is to be made pursuant to other provisions of this Section 4.4(ii)(2),
except as contemplated below, no further adjustment of the Exercise Price shall be made by reason
of such issue or sale.

          (3) Change in Option Price or Rate of Conversion. If the purchase or exercise price provided
for in any Options, the additional consideration, if any, payable upon the issue, conversion,
exercise or exchange of any Convertible Securities, or the rate at which any Convertible Securities
are convertible into or exercisable or exchangeable for shares of Common Stock increases or
decreases at any time, the Exercise Price in effect at the time of such increase or decrease shall
be adjusted to the Exercise Price which would have been in effect at such time had such Options or
Convertible Securities provided for such increased or decreased purchase price, additional
consideration or increased or decreased conversion rate, as the case may be, at the time initially
granted, issued or sold. For purposes of this Section 4.4(ii)(3), if the terms of any Option or
Convertible Security that was outstanding as of the date of issuance of this Warrant are increased
or decreased in the manner described in the immediately preceding sentence, then such Option or
Convertible Security and the shares of Common Stock deemed issuable upon exercise, conversion or
exchange thereof shall be deemed to have been issued as of the date of such increase or decrease.
No adjustment pursuant to this Section 4.4(ii)(3) shall be made if such adjustment would result in
an increase of the Exercise Price then in effect.

          (4) Calculation of Consideration Received. If any Option or Convertible Security or Adjustment
Right is issued in connection with the issuance or sale or deemed issuance or sale of any other
securities of the Company, together comprising one integrated transaction, (x) such Option or
Convertible Security (as applicable) or Adjustment Right (as applicable) will be deemed to have
been issued for consideration equal to the Black Scholes Consideration Value thereof and (y) the
other securities issued or sold or deemed to have been issued or sold in such integrated
transaction shall be deemed to have been issued for consideration equal to the difference of (I)
the aggregate consideration received or receivable by the Company minus (II) the Black Scholes
Consideration Value of each such Option or Convertible Security (as applicable) or Adjustment Right
(as applicable). If any shares of Common Stock, Options or Convertible Securities are issued or
sold or deemed to have been issued or sold for cash, the consideration received therefor will be
deemed to be the net amount of consideration received by the Company therefor. If any shares of
Common Stock, Options or Convertible Securities are issued or sold for a consideration other than
cash, the amount of such consideration received by the Company will be the fair value of such
consideration, except
where such consideration consists of publicly traded securities, in which case the amount of
consideration received by the Company for such securities will be the arithmetic average of the
VWAPs of such security for each of the five (5) Trading Days immediately preceding the date of

 

 

receipt. If any shares of Common Stock, Options or Convertible Securities are issued to the owners
of the non-surviving entity in connection with any merger in which the Company is the surviving
entity, the amount of consideration therefor will be deemed to be the fair value of such portion of
the net assets and business of the non-surviving entity as is attributable to such shares of Common
Stock, Options or Convertible Securities, as the case may be. The fair value of any consideration
other than cash or publicly traded securities will be determined jointly by the Company and the
registered holder. If such parties are unable to reach agreement within ten (10) days after the occurrence of
an event requiring valuation (the “Valuation Event”), the fair value of such consideration will be
determined within five (5) Trading Days after the tenth (10th) day following such Valuation Event
by an independent, reputable appraiser jointly selected by the Company and the registered holder. The
determination of such appraiser shall be final and binding upon all parties absent manifest error
and the fees and expenses of such appraiser shall be borne by the Company. For purposes hereof,
“Black Scholes Consideration Value” means the value of the applicable Option or Convertible
Security (as the case may be) as of the date of issuance thereof calculated using the Black Scholes
Option Pricing Model obtained from the “OV” function on Bloomberg utilizing (i) an underlying price
per share equal to the Closing Sale Price of the Common Stock on the Trading Day immediately
preceding the public announcement of the execution of definitive documents with respect to the
issuance of such Option or Convertible Security (as the case may be), (ii) a risk-free interest
rate corresponding to the U.S. Treasury rate for a period equal to the remaining term of such
Option or Convertible Security (as the case may be) as of the date of issuance of such Option or
Convertible Security (as the case may be) and (iii) an expected volatility equal to the greater of
100% and the 30 day volatility obtained from the HVT function on Bloomberg (determined utilizing a
365 day annualization factor) as of the Trading Day immediately following the date of issuance of
such Option or Convertible Security (as the case may be).

               (5) Record Date. If the Company takes a record of the holders of shares of Common Stock for
the purpose of entitling them (A) to receive a dividend or other distribution payable in shares of
Common Stock, Options or in Convertible Securities or (B) to subscribe for or purchase shares of
Common Stock, Options or Convertible Securities, then such record date will be deemed to be the
date of the issue or sale of the shares of Common Stock deemed to have been issued or sold upon the
declaration of such dividend or the making of such other distribution or the date of the granting
of such right of subscription or purchase (as the case may be).

          (iii) Notwithstanding the foregoing, no adjustment will be made under this Section 4.4 in
respect of: (i) the issuance of securities upon the exercise or conversion of any Common Stock or
Common Stock Equivalents issued by the Company on or prior to the date hereof provided that the
terms of such Common Stock or Common Stock Equivalents are not amended, modified or changed on or
after the date hereof, (ii) the grant of options, warrants, Common Stock or other Common Stock
Equivalents (but not including any amendments to such instruments) under any duly authorized
Company stock option, restricted stock plan or stock purchase plan whether now existing or
hereafter approved by the Company and its stockholders in the future, and the
issuance of Common Stock in respect thereof, or as an inducement grant to new employees,
consultants, directors or officers, (iii) the issuance of securities in connection with a Strategic
Transaction, or (iv) the issuance of securities in a transaction described in Section 4.1 or 4.2

 

 

(collectively, “Excluded Issuances”). For purposes of this paragraph, a “Strategic Transaction”
means a transaction or relationship in which (1) the Company issues shares of Common Stock to a
Person (or a shareholder, partner, member or other owner thereof) that the Board of Directors of
the Company determined in good faith is, itself or through its Subsidiaries, an operating company
in a business synergistic with the business of the Company or is a commercial bank and (2) the
Company expects to receive benefits in addition to the investment of funds, but shall not include a
transaction in which the Company is issuing securities primarily for the purpose of raising capital
or to a Person whose primary business is investing in securities.

     4.5 Notices of Changes in Warrant. Upon every adjustment of the Exercise Price or the
number of shares issuable upon exercise of a Warrant, the Company shall give written notice thereof
to the Warrant Agent, which notice shall state the Exercise Price resulting from such adjustment
and the increase or decrease, if any, in the number of shares purchasable at such price upon the
exercise of a Warrant, setting forth in reasonable detail the method of calculation and the facts
upon which such calculation is based. Upon the occurrence of any event specified in Sections 4.1,
4.2, 4.3 and 4.4, then, in any such event, the Company shall give written notice to each Warrant
holder, at the last address set forth for such holder in the Warrant Register, of the record date
or the effective date of the event, and, upon written request, provide such holder with a copy of
the notice provided to the Warrant Agent. Failure to give such notice, or any defect therein, shall
not affect the legality or validity of such event.

     4.6 No Fractional Shares. Notwithstanding any provision contained in this Warrant
Agreement to the contrary, the Company shall not issue fractional shares upon exercise of Warrants.
If the holder of any Warrant would be entitled, upon the exercise of such Warrant, to receive a
fractional interest in a share, the Company shall, upon such exercise, round down to the nearest
whole number the number of shares of Common Stock to be issued to the Warrant holder and shall pay
the holder in cash the fair market value (based on the Closing Sales Prices) for any such
fractional shares.

5. Transfer and Exchange of Warrants.

     5.1 Registration of Transfer. The Warrant Agent shall register the transfer, from time
to time, of any outstanding Warrant in the Warrant Register, upon surrender of such Warrant for
transfer, properly endorsed with signatures properly guaranteed and accompanied by appropriate
instructions for transfer. Upon any such transfer, a new Warrant representing an equal aggregate
number of Warrants shall be issued and the old Warrant shall be cancelled by the Warrant Agent. The
Warrants so cancelled shall be delivered by the Warrant Agent to the Company from time to time upon
request.

     5.2 Charges, Taxes and Expenses. No charges shall be made for any issuance and
delivery of shares of Common Stock upon exercise of the Warrant for any issue or transfer tax,
transfer agent fee or other incidental tax or expense in respect of the issuance of such shares,
all of which taxes and expenses shall be paid by the Company; provided, however, that the
Company shall not be required to pay any tax that may be payable in respect of any transfer
involved in the registration of any Warrant Shares or the Warrants in a name other than that of the
registered holder or an affiliate thereof. The registered holder shall be responsible for all

 

 

other tax liability that may arise as a result of holding or transferring the Warrant or receiving
Warrant Shares upon exercise hereof.

     5.3 Warrant Execution and Countersignature. The Warrant Agent is hereby authorized to
countersign and to deliver, in accordance with the terms of this Agreement, the Warrants required
to be issued pursuant to the provisions of this Section 5, and the Company, whenever required by
the Warrant Agent, will supply the Warrant Agent with Warrants duly executed on behalf of the
Company for such purpose.

6. Other Provisions Relating to Rights of Holders of Warrants.

     6.1 No Rights as Stockholder. A Warrant does not entitle the registered holder thereof
to any of the rights of a stockholder of the Company, including the right to receive dividends, or
other distributions, exercise any preemptive rights to vote or to consent or to receive notice as
stockholders in respect of the meetings of stockholders or the election of directors of the Company
or any other matter.

     6.2 Lost, Stolen, Mutilated, or Destroyed Warrants. If a Warrant is mutilated, lost,
stolen or destroyed, the Company and the Warrant Agent shall issue or cause to be issued in
exchange and substitution for and upon cancellation thereof, or in lieu of and substitution for the
Warrant, a New Warrant, but only upon receipt of evidence reasonably satisfactory to the Company of
such loss, theft or destruction (in such case) and, in each case, a customary and reasonable
indemnity or surety bond, if requested by the Company.

     6.3 Reservation of Common Stock. The Company shall at all times reserve and keep
available a number of its authorized but unissued shares of Common Stock that will be sufficient to
permit the exercise in full of all outstanding Warrants issued pursuant to this Agreement.

7. Concerning the Warrant Agent and Other Matters.

     7.1 Payment of Taxes. The Company will from time to time promptly pay all taxes and
charges that may be imposed upon the Company or the Warrant Agent in respect of the issuance or
delivery of shares of Common Stock upon the exercise of Warrants, but the Company shall not be
obligated to pay any transfer taxes in respect of the Warrants or such shares.

     7.2 Resignation, Consolidation, or Merger of Warrant Agent.

          7.2.1 Appointment of Successor Warrant Agent. The Warrant Agent, or any successor to
it hereafter appointed, may resign its duties and be discharged from all further duties and
liabilities hereunder after giving sixty (60) days’ notice in writing to the Company. If the office
of the Warrant Agent becomes vacant by resignation or incapacity to act or otherwise, the Company
shall appoint in writing a successor Warrant Agent in place of the Warrant Agent. If
the Company shall fail to make such appointment within a period of 30 days after it has been
notified in writing of such resignation or incapacity by the Warrant Agent or by the holder of the
Warrant (who shall, with such notice, submit his, her or its Warrant for inspection by the

 

 

Company), then the holder of any Warrant may apply to the Supreme Court of the State of New York
for the County of New York for the appointment of a successor Warrant Agent at the Company’s cost.
Any successor Warrant Agent, whether appointed by the Company or by such court, shall be a
corporation organized and existing under the laws of the State of New York, in good standing and
having its principal office in the Borough of Manhattan, City and State of New York, and authorized
under such laws to exercise corporate trust powers and subject to supervision or examination by
federal or state authority. After appointment, any successor Warrant Agent shall be vested with all
the authority, powers, rights, immunities, duties, and obligations of its predecessor Warrant Agent
with like effect as if originally named as Warrant Agent hereunder, without any further act or
deed; but if for any reason it becomes necessary or appropriate, the predecessor Warrant Agent
shall execute and deliver, at the expense of the Company, an instrument transferring to such
successor Warrant Agent all the authority, powers, and rights of such predecessor Warrant Agent
hereunder; and upon request of any successor Warrant Agent the Company shall make, execute,
acknowledge, and deliver any and all instruments in writing for more fully and effectually vesting
in and confirming to such successor Warrant Agent all such authority, powers, rights, immunities,
duties, and obligations.

          7.2.2 Notice of Successor Warrant Agent. In the event a successor Warrant Agent shall
be appointed, the Company shall give notice thereof to the predecessor Warrant Agent and the
transfer agent for the Common Stock not later than the effective date of any such appointment.

          7.2.3 Merger or Consolidation of Warrant Agent. Any corporation into which the Warrant
Agent may be merged or with which it may be consolidated or any corporation resulting from any
merger or consolidation to which the Warrant Agent shall be a party shall be the successor Warrant
Agent under this Agreement without any further act.

     7.3 Fees and Expenses of Warrant Agent.

          7.3.1 Remuneration. The Company agrees to pay the Warrant Agent reasonable
remuneration for its services as such Warrant Agent hereunder and will reimburse the Warrant Agent
upon demand for all expenditures that the Warrant Agent may reasonably incur in the execution of
its duties hereunder.

          7.3.2 Further Assurances. The Company agrees to perform, execute, acknowledge and
deliver or cause to be performed, executed, acknowledged and delivered all such further and other
acts, instruments and assurances as may reasonably be required by the Warrant Agent for the
carrying out or performing of the provisions of this Agreement.

     7.4 Liability of Warrant Agent.

          7.4.1 Reliance on Company Statement. Whenever in the performance of its duties under
this Warrant Agreement the Warrant Agent shall deem it necessary or desirable that
any fact or matter be proved or established by the Company prior to taking or suffering any
action hereunder, such fact or matter (unless other evidence in respect thereof be herein
specifically prescribed) may be deemed to be conclusively proved and established by a statement

 

 

signed by the President or Chairman of the Board of the Company and delivered to the Warrant Agent.
The Warrant Agent may rely upon such statement for any action taken or suffered in good faith by it
pursuant to the provisions of this Agreement.

          7.4.2 Indemnity. The Warrant Agent shall be liable hereunder only for its own gross
negligence, willful misconduct or bad faith. The Company agrees to indemnify the Warrant Agent and
save it harmless against any and all liabilities, including judgments, costs and reasonable counsel
fees, for anything done or omitted by the Warrant Agent in the execution of this Agreement, except
as a result of the Warrant Agent’s gross negligence, willful misconduct or bad faith.

          7.4.3 Exclusions. The Warrant Agent shall have no responsibility with respect to the
validity of this Agreement or with respect to the validity or execution of any Warrant (except its
countersignature thereof); nor shall it be responsible for any breach by the Company of any
covenant or condition contained in this Agreement or in any Warrant; nor shall it be responsible to
make any adjustments required under the provisions of Section 4 hereof or responsible for the
manner, method or amount of any such adjustment or the ascertaining of the existence of facts that
would require any such adjustment; nor shall it by any act hereunder be deemed to make any
representation or warranty as to the authorization or reservation of any shares of Common Stock to
be issued pursuant to this Agreement or any Warrant or as to whether any shares of Common Stock
will when issued be valid and fully paid and nonassessable.

     7.5 Acceptance of Agency. The Warrant Agent hereby accepts the agency established by
this Agreement and agrees to perform the same upon the terms and conditions herein set forth and,
among other things, shall account promptly to the Company with respect to Warrants exercised and
concurrently account for, and pay to the Company, all moneys received by the Warrant Agent for the
purchase of shares of Common Stock through the exercise of Warrants.

     7.6 Waiver. The Warrant Agent hereby waives any and all right, title, interest or
claim of any kind (“Claim”) in or to any distribution of the Trust Account (as defined in that
certain Investment Management Trust Agreement, dated as of the date hereof, by and between the
Company and the Warrant Agent, as trustee thereunder), and hereby agrees not to seek recourse,
reimbursement, payment or satisfaction for any Claim against the Trust Account for any reason
whatsoever.

8. Limitations on Exercise.

     8.1 Notwithstanding anything to the contrary contained herein, the Warrant shall not be
exercisable by the registered holder to the extent (but only to the extent) that the registered
holder or any of its affiliates would beneficially own in excess of 4.99% (the “Maximum
Percentage”) of the Common Stock. To the extent the above limitation applies, the determination of
whether the Warrant shall be exercisable (vis-à-vis other convertible, exercisable or
exchangeable securities owned by the registered holder or any of its affiliates) and of which
such securities shall be exercisable (as among all such securities owned by the registered holder)
shall, subject to such Maximum Percentage limitation, be determined on the basis of the first

 

 

submission to the Company for conversion, exercise or exchange (as the case may be). No prior
inability to exercise the Warrant pursuant to this paragraph shall have any effect on the
applicability of the provisions of this paragraph with respect to any subsequent determination of
exercisability. For the purposes of this paragraph, beneficial ownership and all determinations and
calculations (including, without limitation, with respect to calculations of percentage ownership)
shall be determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as
amended, and the rules and regulations promulgated thereunder. The provisions of this paragraph
shall be implemented in a manner otherwise than in strict conformity with the terms of this
paragraph to correct this paragraph (or any portion hereof) which may be defective or inconsistent
with the intended Maximum Percentage beneficial ownership limitation herein contained or to make
changes or supplements necessary or desirable to properly give effect to such Maximum Percentage
limitation. The limitations contained in this paragraph shall apply to a successor holder of the
Warrant. The holders of Common Stock shall be third party beneficiaries of this paragraph and the
Company may not waive this paragraph without the consent of holders of a majority of the
outstanding shares of Common Stock. For any reason at any time, upon the written or oral request of
the registered holder, the Company shall within one (1) Business Day confirm orally and in writing
to the registered holder the number of shares of Common Stock then outstanding, including by virtue
of any prior conversion or exercise of convertible or exercisable securities into Common Stock. By
written notice to the Company, any registered holder may increase or decrease the Maximum
Percentage to any other percentage not in excess of 9.99% specified in such notice; provided that
(i) any such increase will not be effective until the 61st day after such notice is delivered to
the Company, and (ii) any such increase or decrease will apply only to the registered holder
sending such notice and not to any other holder. It shall not be the responsibility of the Warrant
Agent to monitor the limitations on exercises imposed by this Section 8.1.

9. Miscellaneous Provisions.

     9.1 Successors. All the covenants and provisions of this Agreement by or for the
benefit of the Company or the Warrant Agent shall bind and inure to the benefit of their respective
successors and assigns.

     9.2 Notices. Any notice, statement or demand authorized by this Warrant Agreement to
be given or made by the Warrant Agent or by the holder of any Warrant to or on the Company shall be
delivered by hand or sent by facsimile, registered or certified mail or overnight courier service,
addressed (until another address is filed in writing by the Company with the Warrant Agent) as
follows:

Aastrom Biosciences, Inc.

24 Frank Lloyd Wright Drive

P.O. Box 376

Ann Arbor, MI 48106

Attn: President

Any notice, statement or demand authorized by this Agreement to be given or made by the holder of
any Warrant or by the Company to or on the Warrant Agent shall be delivered by

 

 

facsimile, hand or
sent by registered or certified mail or overnight courier service, addressed (until another address
is filed in writing by the Company with the Warrant Agent) as follows:

Continental Stock Transfer & Trust Company

17 Battery Place

New York, New York 10004

Attn: Compliance Department

Any notice, statement or demand authorized by this Agreement to be given or made by the Company or
by the Warrant Agent to or on the holder of any Warrant shall be delivered by facsimile, hand or
sent by registered or certified mail or overnight courier service, addressed (until another address
is filed in writing by the holder with the Warrant Agent) as set forth on the Warrant Register

Any notice, sent pursuant to this Warrant Agreement shall be effective, if delivered by hand, upon
receipt thereof by the party to whom it is addressed, if sent by facsimile, on the date sent , by
overnight courier, on the next business day of the delivery to the courier, and if sent by
registered or certified mail on the third day after registration or certification thereof.

     9.3 Applicable Law. The validity, interpretation and performance of this Agreement and
of the Warrants shall be governed in all respects by the laws of the State of New York, without
giving effect to conflicts of law principles that would result in the application of the
substantive laws of another jurisdiction. The Company hereby agrees that any action, proceeding or
claim against it arising out of or relating in any way to this Agreement shall be brought and
enforced in the courts of the State of New York or the United States District Court for the
Southern District of New York, and irrevocably submits to such jurisdiction, which jurisdiction
shall be exclusive. The Company hereby waives any objection to such exclusive jurisdiction and that
such courts represent an inconvenient forum. Any such process or summons to be served upon the
Company may be served by transmitting a copy thereof by registered or certified mail, return
receipt requested, postage prepaid, addressed to it at the address set forth in Section 9.2 hereof.
Such mailing shall be deemed personal service and shall be legal and binding upon the Company in
any action, proceeding or claim.

     9.4 Persons Having Rights under this Agreement. Except as provided in Section 8.1
hereof, nothing in this Agreement expressed and nothing that may be implied from any of the
provisions hereof is intended, or shall be construed, to confer upon, or give to, any person or
corporation other than the parties hereto and the registered holders of the Warrants any right,
remedy, or claim under or by reason of this Warrant Agreement or of any covenant, condition,
stipulation, promise, or agreement hereof. Except as provided in Section 8.1 hereof, all
covenants, conditions, stipulations, promises, and agreements contained in this Warrant
Agreement shall be for the sole and exclusive benefit of the parties hereto and their
successors and assigns and of the registered holders of the Warrants.

 

 

     9.5 Examination of the Warrant Agreement. A copy of this Agreement shall be available
at all reasonable times at the office of the Warrant Agent in the Borough of Manhattan, City and
State of New York, for inspection by the registered holder of any Warrant. The Warrant Agent may
require any such holder to submit his, her or its Warrant for inspection by it.

     9.6 Counterparts. This Agreement may be executed in any number of original or
facsimile counterparts and each of such counterparts shall for all purposes be deemed to be an
original, and all such counterparts shall together constitute but one and the same instrument.

     9.7 Effect of Headings. The section headings herein are for convenience only and are
not part of this Warrant Agreement and shall not affect the interpretation thereof.

     9.8 Amendments. This Agreement may be amended by the parties hereto without the
consent of any registered holder for the purpose of curing any ambiguity, or curing, correcting or
supplementing any defective provision contained herein or adding or changing any other provisions
with respect to matters or questions arising under this Agreement as the parties may deem necessary
or desirable and that the parties deem shall not adversely affect the interest of the registered
holders. All other modifications or amendments shall require the written consent of the registered
holders of a sixty-seven percent (67%) of the then outstanding Warrants; provided that no
modification or amendment that would (i) increase the Exercise Price, (ii) shorten the Exercise
Period, or (iii) alter any other provision of this Agreement which provides for a monetary value to
a registered holder shall be valid without such registered holder’s consent.

     9.9 Severability. Whenever possible, each provision of this Agreement shall be
interpreted in such manner as to be effective and valid under applicable law, but if any provision
of this Agreement is held to be prohibited by or invalid under applicable law, such provision shall
be ineffective only to the extent of such prohibition or invalidity, without invalidating the
remainder of this Agreement.

     9.10 Dispute Resolution. In the case of a dispute as to the determination of the
Exercise Price, the Closing Sale Price, Black Scholes Value, Black Scholes Consideration Value, or
fair market value or the arithmetic calculation of the Warrant Shares (as the case may be), the
Company or the registered holder (as the case may be) shall submit the disputed determinations or
arithmetic calculations (as the case may be) via facsimile (i) within two (2) Business Days after
receipt of the applicable notice giving rise to such dispute to the Company or the registered
holder (as the case may be) or (ii) if no notice gave rise to such dispute, at any time after the
registered holder learned of the circumstances giving rise to such dispute (including, without
limitation, as to whether any issuance or sale or deemed issuance or sale was an issuance or sale
or deemed issuance or sale in respect of an Excluded Issuance). If the registered holder and the
Company are unable to agree upon such determination or calculation (as the case may be) of the
Exercise Price, the Closing Sale Price, the Bid Price or fair market value or the number of Warrant
Shares (as the case may be) within three (3) Business Days of such disputed determination or
arithmetic calculation being submitted to the Company or the registered holder (as the
case may be), then the Company shall, within two (2) Business Days submit via facsimile (a)
the disputed determination of the Exercise Price, the Closing Sale Price, or fair market value (as
the case may be) to an independent, reputable investment bank selected by the registered holder or (b) the

 

 

disputed arithmetic calculation of the Warrant Shares to the Company’s independent, outside
accountant. The Company shall cause at its expense the investment bank or the accountant (as the
case may be) to perform the determinations or calculations (as the case may be) and notify the
Company and the registered holder of the results no later than ten (10) Business Days from the time it
receives such disputed determinations or calculations (as the case may be). Such investment bank’s
or accountant’s determination or calculation (as the case may be) shall be binding upon all parties
absent demonstrable error.

[Signature page follows]

 

 

     IN WITNESS WHEREOF, this Agreement has been duly executed by the parties hereto as of the day
and year first above written.

	 	 	 	 	 
	 	AASTROM BIOSCIENCES, INC.

 	 
	 	By:  	/s/ Timothy Mayleben 	 
	 	 	Name:  	Timothy M. Mayleben 	 
	 	 	Title:  	President and Chief Executive Officer 	 
	 
	 	CONTINENTAL STOCK TRANSFER & TRUST COMPANY

 	 
	 	By:  	/s/ Leslie DeLuca 	 
	 	 	Name:  	Leslie A. DeLuca 	 
	 	 	Title:  	Vice President 	 

 

 

	 	 	 	 	 

Exhibit A

EXERCISABLE ON OR AFTER DECEMBER 15, 2010

AND ON OR BEFORE DECEMBER 15, 2015 (THE EXPIRATION DATE)

WARRANTS

TO ACQUIRE _______ SHARES OF COMMON STOCK OF

AASTROM BIOSCIENCES, INC.

Warrant
Certificate No.:
          
CUSIP: 00253U 164

This Warrant Certificate certifies that      , or registered assigns, is the registered holder of a
Warrant (the “Warrant”) to acquire from Aastrom Biosciences, Inc., a Michigan corporation (the
“Company”), the number of fully paid and non-assessable shares of Common Stock, no par value, of
the Company (the “Common Stock”) specified above for consideration equal to the Exercise Price (as
defined in the Warrant Agreement) per share of Common Stock. The Exercise Price and number of
shares of Common Stock and/or type of securities or property issuable upon exercise of the Warrant
are subject to adjustment upon the occurrence of certain events as set forth in the Warrant
Agreement. The Warrant evidenced by this Warrant Certificate shall not be exercisable after and
shall terminate and become void as of 5:30 P.M., New York time, on the Expiration Date.

The Warrant evidenced by this Warrant Certificate is part of a duly authorized issue of warrants
expiring on the Expiration Date entitling the registered holder hereof to receive shares of Common
Stock, and is issued or to be issued pursuant to a Warrant Agreement dated December 15, 2010 (the
“Warrant Agreement”), duly executed and delivered by the Company to Continental Stock Transfer &
Trust Company, as warrant agent (the “Warrant Agent”, which term includes any successor Warrant
Agent under the Warrant Agreement), which Warrant Agreement is hereby incorporated by reference in
and made a part of this instrument and is hereby referred to for a description of the rights,
limitation of rights, obligations, duties and immunities thereunder of the Warrant Agent, the
Company and the registered holders (“Holders” meaning, from time to time, the registered holders of
the warrant issued thereunder). To the extent any provisions of this Warrant Certificate conflicts
with any provision of the Warrant Agreement, the provisions of the Warrant Agreement shall apply. A
copy of the Warrant Agreement may be obtained by the Holder hereof upon written request to the
Company at 24 Frank Lloyd Wright Drive, P.O. Box 376, Ann Arbor, MI 48106. Capitalized terms not
defined herein have the meanings ascribed thereto in the Warrant Agreement.

This Warrant may be exercised, in whole or in part, at any time on or after December 15, 2010 and
on or before December 15, 2015 (the “Expiration Date”), subject to the terms of the Warrant
Agreement including, but not limited to, Section 3 thereof, by delivering the Form of Election to
Purchase set forth hereon properly completed and executed in accordance with Section 3 of the
Warrant Agreement. Each exercise must be for a whole number of Warrant Shares. In the event that
upon any exercise of the Warrant evidenced hereby the number of shares of Common Stock acquired
shall be less than the total number of shares of Common Stock which may be purchased pursuant to
this Warrant, there shall be issued to the Holder hereof or such Holder’s assignee a new Warrant
Certificate evidencing the unexercised portion of this Warrant.

 

 

The Warrant Agreement provides that upon the occurrence of certain events the Exercise Price set
forth on this Warrant Certificate may, subject to certain conditions, be adjusted, and that upon
the occurrence of certain events the number of shares of Common Stock and/or the type of securities
or other property issuable upon the exercise of this Warrant shall be adjusted. No fractions of a
share of Common Stock will be issued upon the exercise of this Warrant, but the Company will pay
the cash value thereof determined as provided in the Warrant Agreement.

Warrant Certificates, when surrendered at the office of the Warrant Agent by the registered Holder
thereof in person or by such Holder’s legal representative or attorney duly appointed and
authorized in writing, may be exchanged, in the manner and subject to the limitations provided in
the Warrant Agreement, but without payment of any service charge, for another Warrant Certificate
or Warrant Certificates of like tenor evidencing in the aggregate the right to purchase a like
number of Warrant Shares.

Each taker and holder of this Warrant Certificate, by taking or holding the same, consents and
agrees that the holder of this Warrant Certificate when duly endorsed in blank may be treated by
the Company, the Warrant Agent and all other persons dealing with this Warrant Certificate as the
absolute owner hereof for any purpose and as the person entitled to exercise the rights represented
hereby or the person entitled to the transfer hereof on the register of the Company maintained by
the Warrant Agent, any notice to the contrary notwithstanding, provided that until such transfer on
such register, the Company and the Warrant Agent may treat the registered Holder hereof as the
owner for all purposes.

This Warrant does not entitle any Holder to any of the rights of a shareholder of the Company.

This Warrant and the Warrant Agreement are subject to amendment as provided in the Warrant
Agreement.

This Warrant Certificate shall not be valid or obligatory for any purpose until it shall have been
countersigned by the Warrant Agent.

[The remainder of this page has been left intentionally blank.]

 

 

     IN WITNESS WHEREOF, the undersigned have caused this Warrant Certificate to be executed as of
the date set forth below.

	 	 	 	 	 
	 	AASTROM BIOSCIENCES, INC.

 	 
	 	By:  	 	 
	 	 	Name:  	 	 
	 	 	Title:  	 	 
	 

	 	 	 	 	 
	Countersigned:

CONTINENTAL STOCK TRANSFER & TRUST COMPANY

 
	By:  	 	 
	 	Name:  	 	 
	 	Title:  	 	 

 

 

	 	 	 	 	 

FORM OF ELECTION TO EXERCISE

To Aastrom Biosciences, Inc.:

In accordance with the Warrant Certificate enclosed with this Form of Election to Exercise, the
undersigned hereby irrevocably elects to exercise the Warrant with respect to  Warrant
Shares in accordance with the terms of the Warrant Agreement.

1. Form of Exercise Price. The Holder intends that payment of the Exercise Price shall be made as:

                a Cash Exercise; or

                a Cashless Exercise.

2. Payment of Exercise Price. In the event that the Holder has elected a Cash Exercise with respect
to some or all of the Warrant Shares to be issued pursuant hereto, the Holder shall pay the
Aggregate Exercise Price, in lawful money of the United States, by certified check or bank draft
payable to the order of the Company or via wire transfer of immediately available funds payable to the order of the Company (or as otherwise agreed to by the Company) delivered to the
Warrant Agent, together with any applicable taxes payable by the undersigned pursuant to the
Warrant.

The undersigned requests that certificates for the shares of Common Stock issuable upon this
exercise be issued in the name of

	 	 	 	 	 

	Name:
	 	 	 	 
	 

	 	 

	 	 
	Address:
	 	 	 	 
	 

	 	 

	 	 
	 

	 	 

	 	 
	 

	 	 

	 	 

Social Security or Tax I.D. No.: ______________Exhibit 10.1

Exhibit 10.1

CONSENT, WAIVER AND FOURTH AMENDMENT TO CREDIT AGREEMENT

CONSENT, WAIVER AND FOURTH AMENDMENT TO CREDIT AGREEMENT (this “Amendment”), dated as
of December 10, 2010, is executed by and among LAWSON PRODUCTS, INC., a Delaware corporation
(“Lawson”), which has its chief executive office located at 1666 E. Touhy Avenue, Des
Plaines, Illinois 60018, various subsidiaries of Lawson listed on the signature pages hereto
(Lawson and the subsidiaries are referred to collectively herein as the “Borrower” or the
“Borrowers”), THE PRIVATEBANK AND TRUST COMPANY both as a lender and as agent (in such
capacity, the “Agent”), for itself and all other lenders from time to time a party hereto
(“Lenders”), located at 120 South LaSalle Street, Chicago, Illinois 60603-3400, and all
other Lenders.

WHEREAS, the Agent, Lawson and certain subsidiaries of Lawson (together with Lawson,
collectively, the “Original Borrowers”), entered into a Credit Agreement, dated as of
August 21, 2009, among the Original Borrowers, the Agent and the Lenders, and on December 2, 2009,
Lawson Products, Inc., an Illinois corporation and newly-formed wholly-owned subsidiary of Lawson
(“Lawson IL”), became a party to such agreement as a Borrower (herein, as the same may be
amended, modified or supplemented from time to time, the “Credit Agreement”); and

WHEREAS, the Borrowers consummated an internal reorganization pursuant to which several of the
Borrowers were merged into Lawson IL and assets of certain of the Borrowers were transferred among
the Borrowers; and

WHEREAS, the Borrowers, the Lenders and the Agent entered into a Consent, Waiver and First
Amendment to Credit Agreement dated as of December 31, 2009; and

WHEREAS, the Borrowers, the Lenders and the Agent entered into a Second Amendment to Credit
Agreement dated as of January 29, 2010; and

WHEREAS, the Borrowers, the Lenders and the Agent entered into a Consent Waiver and Third
Amendment to Credit Agreement dated as of September 1, 2010 with respect to the sale of certain
assets and liabilities of Assembly Component Systems, Inc., an Illinois corporation, during the
third quarter of Lawson’s fiscal 2010; and

WHEREAS, the Borrowers have informed the Agent that they intend to consummate the sale of all
or substantially all of the assets of Rutland Tool and Supply Co., a Nevada corporation
(“Rutland”) on or about December 10, 2010 (the “Sale”); and

WHEREAS, the Borrowers, the Lenders and the Agent wish to enter into this Amendment to (i)
confirm each Lender’s and the Agent’s consent to the Sale, (ii) waive any and all Events of Default
arising or occurring under the Credit Agreement or any other Loan Document solely in connection
with the Sale and (iii) amend the Credit Agreement to account for the Sale and otherwise as set
forth herein.

NOW THEREFORE, in consideration of the premises and the mutual covenants hereinafter contained
in this Amendment, the parties hereto hereby agree as follows:

 

 

 

1. Incorporation of the Agreement. All capitalized terms which are not defined
hereunder shall have the same meanings as set forth in the Credit Agreement, and the Credit
Agreement, to the extent not inconsistent with this Amendment, is incorporated herein by this
reference as though the same were set forth in its entirety. To the extent any terms and
provisions of the Credit Agreement are inconsistent with the amendments set forth in Paragraph
2 below, such terms and provisions shall be deemed superseded hereby. Except as specifically
set forth herein, the Credit Agreement and the other Loan Documents shall remain in full force and
effect and the provisions thereof shall be binding on the parties hereto.

2. Amendments to the Credit Agreement. The parties hereto hereby amend the Credit
Agreement, effective as of the date hereof as follows:

The first sentence of Section 4.1 of the Credit Agreement is deleted and substituted
therefor is the following:

“The Revolving Loans shall be evidenced by Revolving Notes (together with
all renewals, extensions, modifications or substitutions thereof, the
“Revolving Notes”) in the form of Exhibit A attached hereto, duly executed
by each Borrower and payable to the order of each Lender according to such
Lender’s Revolving Loan Commitment.”

3. Representations and Warranties.

	 	(a)	 	The representations and warranties set forth in Section
7 of the Credit Agreement shall be deemed remade and affirmed by the
Borrowers in all material respects, as of the date hereof; provided that
representations and warranties referencing a particular date other than a
general date of execution shall be true and correct as of such date; provided,
further, that any and all references to the Credit Agreement in such
representations and warranties shall be deemed to include this Amendment.

	 
	 	(b)	 	The Borrowers represent and warrant that no Event of Default
has occurred and is continuing.

4. Consent; Waiver. Notwithstanding any terms or provisions of the Credit Agreement
to the contrary, this Amendment serves as evidence of the Agent’s and each Lender’s (i) consent to
the Sale and each of the transactions necessary to consummate the Sale and (ii) waiver of any and
all Events of Default arising or occurring under the Credit Agreement or any other Loan Document,
solely as a result of the Sale. The consent and waiver provided herein shall be limited to the
matter set forth herein. Except as otherwise provided herein, all provisions, terms and conditions
of the Credit Agreement remain in full force and effect after giving effect to the Sale.

5. Fees and Expenses. The Borrowers shall pay or reimburse the Agent for all
reasonable costs and expenses, including, without limitation, legal expenses and reasonable
attorneys’ fees (for outside counsel) incurred by the Agent, or for which the Agent becomes
obligated, in connection with the negotiation, preparation, and closing of this Amendment.

 

2

 

6. Delivery of Documents/Information. This Amendment shall be effective on the date
hereof upon receipt by Agent of the last of the following: (i) a fully executed copy of this
Amendment, (ii) the Revolving Notes executed by each Borrower and payable to the order of each
Lender, and (iii) Borrowers’ payment to Agent of all invoiced fees and expenses and the
modification fee provided in paragraph 5 above.

7. Release of Rutland. The Agent and each Lender hereby agrees and acknowledges that
effective immediately following consummation of the Sale, (i) Rutland shall no longer be a Borrower
under the Credit Agreement or a Grantor under the Security Agreement or otherwise be bound by, or a
party to, any of the Loan Documents, (ii) Rutland shall be deemed released and discharged from any
and all liabilities and obligations under the Loan Documents and (iii) all security interests and
other liens granted to or held by the Agent in any assets or property of Rutland as security for
the Obligations shall be deemed released and discharged, without recourse or warranty. The Agent
agrees and acknowledges that upon the consummation of the Sale, the Agent shall execute and return
to Lawson such releases of liens, discharges, terminations and other release documentation
reasonably requested by Lawson to evidence the release of the Agent’s liens and security interests
in all of the assets and property of Rutland.

8. Continuing Effect. Except as otherwise specifically set out herein, the provisions
of the Credit Agreement and each of the Loan Documents shall remain in full force and effect. The
Borrowers have heretofore executed and delivered to the Agent certain Loan Documents and the
Borrowers hereby acknowledge and agree that, notwithstanding the execution and delivery of this
Amendment, the Loan Documents remain in full force and effect after giving effect to the amendments
set forth in this Amendment and the rights and remedies of the Agent and the Lenders thereunder,
the obligations of each Borrower thereunder and the liens and security interests created and
provided for thereunder remain in full force and effect and shall not be affected, impaired or
discharged hereby. Nothing herein contained shall affect or impair the priority of the liens and
security interests created and provided for in the Loan Documents as to the indebtedness which
would be secured thereby prior to giving effect to this Amendment and which remains secured thereby
after giving effect to this Amendment. Any and all references to the Credit Agreement in each of
the Loan Documents shall be deemed to refer to and include this Amendment.

9. Headings. The headings of this Amendment are for the purposes of reference only
and shall not affect the construction of the Amendment.

10. Counterparts. This Amendment may be executed by one or more of the parties to
this Amendment on any number of separate counterparts and all of said counterparts taken together
shall be deemed to constitute one and the same instrument. Delivery of an executed counterpart of
this Amendment by facsimile or electronic mail shall be equally as effective as delivery of a
manually executed counterpart of this Amendment. Any party delivering an executed counterpart of
this Amendment by facsimile or electronic mail shall also deliver a manually executed counterpart
of this Amendment, but the failure to deliver a manually executed counterpart shall not affect the
validity, enforceability, or binding effect of this Amendment.

11. Governing Law. This Amendment shall be governed by and construed in accordance
with the internal laws (as opposed to the conflict of law provisions) of the State of Illinois.

[SIGNATURE PAGES FOLLOW]

 

 

3

 

(Signature Page to Fourth Amendment to Credit Agreement)

IN WITNESS WHEREOF, the Borrowers, the Agent and each Lender have executed this Amendment as
of the date first above written.

	 	 	 	 	 	 	 	 	 
	BORROWERS:	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	LAWSON PRODUCTS, INC.,	 	LAWSON PRODUCTS, INC.,	 	 
	a Delaware corporation	 	an Illinois corporation	 	 
	 
	 	 	 	 	 	 	 	 
	By:

	 	 	 	By:	 	 	 	 
	 	 	 	 	 	 	 	 
	Name:

	 	Ron Knutson
	 	Name:
	 	Ron Knutson	 	 
	Its:

	 	Senior Vice President and
	 	Its:
	 	Senior Vice President and	 	 
	 

	 	Chief Financial Officer
	 	 	 	Chief Financial Officer	 	 
	 
	 	 	 	 	 	 	 	 
	DRUMMOND AMERICAN LLC,	 	CRONATRON WELDING SYSTEMS LLC,	 	 
	an Illinois limited liability company	 	a North Carolina limited liability company	 	 
	 
	 	 	 	 	 	 	 	 
	By:

	 	 	 	By:	 	 	 	 
	 	 	 	 	 	 	 	 
	Name:

	 	Ron Knutson
	 	Name:
	 	Ron Knutson	 	 
	Its:

	 	Senior Vice President and
	 	Its:
	 	Senior Vice President and	 	 
	 

	 	Chief Financial Officer
	 	 	 	Chief Financial Officer	 	 
	 
	 	 	 	 	 	 	 	 
	RUTLAND TOOL & SUPPLY CO.,	 	AUTOMATIC SCREW MACHINE	 	 
	a Nevada Corporation	 	PRODUCTS COMPANY, INC.,	 	 
	 	 	 	 	an Alabama corporation	 	 
	 
	 	 	 	 	 	 	 	 
	By:

	 	 	 	By:	 	 	 	 
	 	 	 	 	 	 	 	 
	Name:

	 	Ron Knutson
	 	Name:
	 	Ron Knutson	 	 
	Its:

	 	Senior Vice President and
	 	Its:
	 	Senior Vice President and	 	 
	 

	 	Chief Financial Officer
	 	 	 	Chief Financial Officer	 	 

 

4

 

(Signature Page to Fourth Amendment to Credit Agreement)

	 	 	 	 	 
	

AGENT:

THE PRIVATEBANK AND TRUST COMPANY

 	 	 
	By:  	 	 	 
	Name: 	  	 	 	 
	Its: 	 	 	 
	 
	LENDER:

THE PRIVATEBANK AND TRUST COMPANY

 	 	 
	By:  	 	 	 
	Name: 	  	 	 	 
	Its: 	 	 	 
	 

 

5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00182-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00182-of-00352.parquet"}]]